STOCK TITAN
  1. Home
  2. News
  3. SLP

Simulations Plus, Inc. - SLP STOCK NEWS

Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.

Simulations Plus, Inc. (NASDAQ: SLP) is a leading developer of modeling and simulation software and consulting services that support drug discovery, development research, and regulatory submissions. The company collaborates with pharmaceutical organizations to implement a data-driven, strategic modeling methodology that begins in early discovery stages, extends through preclinical and clinical development, and continues into clinical trials and post-approval phases.

Simulations Plus, through its subsidiaries Cognigen Corporation and DILIsym Services, offers a suite of top-ranked, user-friendly software solutions. These include GastroPlus™, ADMET Predictor™, KIWI™, DILIsym®, NAFLDsym®, PKPlus™, and more. These tools bridge data mining and compound library screening with QSAR models and PBPK/TK modeling and simulation in both animals and humans. The company's quantitative systems pharmacology approaches are widely recognized and licensed by regulatory agencies globally.

In addition to software development, Simulations Plus provides consulting and contract research services to the pharmaceutical industry. The company’s operations are divided into two primary segments: software and services. The software segment generates the majority of the company’s revenue.

Over the past 20 years, Simulations Plus has consistently partnered with clients to reduce costs and accelerate research timelines. The company’s innovative technology and methodologies have earned it a reputation as a reliable partner in the pharmaceutical industry.

Latest News: Simulations Plus continues to make headlines with its innovative solutions and strategic partnerships. Stay updated with the latest developments and achievements of Simulations Plus on our news section.

News

U.S. FDA Renews DILIsym® Software Licenses for 7th Year

Rhea-AI Summary
Simulations Plus, Inc. (SLP) announces the FDA renewal of DILIsym software licenses, a key tool for predicting drug-induced liver injury risk. The software aids in evaluating potential DILI risk, understanding compound mechanisms, and tailoring dosing strategies for efficacy and safety. Dr. Watkins highlights the importance of predicting safe dosing regimens for effective therapies. The incorporation of quantitative systems pharmacology and toxicology models by the FDA showcases the industry's shift towards advanced evaluation tools.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.61%
Tags
none
-
News

Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results

Rhea-AI Summary
Simulations Plus (SLP) reports strong financial results for Q2 fiscal 2024, with total revenue of $18.3 million and diluted EPS of $0.20. The company maintains full-year revenue guidance of $66 to $69 million and EPS guidance of $0.66 to $0.68. Revenue increased by 16% compared to Q2 2023, driven by growth in software and services segments. The company's management remains optimistic about future demand and strategic investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.61%
Tags
earnings
-
News

Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date

Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) will announce its second-quarter fiscal 2024 financial results on April 3, 2024, after the market closes. A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
earnings
News

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Rhea-AI Summary
Simulations Plus, Inc. (SLP) CEO to host fireside chat at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum. Live webcast available for replay for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
conferences
-
News

Simulations Plus and the University of Bath Awarded New FDA Grant

Rhea-AI Summary
Simulations Plus, Inc. (SLP) partners with the University of Bath and other institutions to develop an enhanced dermal PBBM/PBPK model for topical products, funded by the FDA. The collaboration aims to revolutionize drug product performance prediction, expedite regulatory decisions, and benefit patients and the pharmaceutical industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
none
-
News

Simulations Plus Extends Collaboration with Major Toxicology Research Agency

Rhea-AI Summary
Simulations Plus extends agreement with NIEHS for research project on chemical safety assessment utilizing computational tools like ADMET Predictor and GastroPlus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
News

Simulations Plus Launches Corporate Development Initiative

Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) announces a strategic shift towards investing in early-stage companies to drive innovation and collaboration. The company aims to enhance innovation, grow its M&A pipeline, expand revenue opportunities, and drive shareholder returns through strategic investments and partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.63%
Tags
none
-
News

Simulations Plus to Participate in Upcoming Healthcare Conferences

Rhea-AI Summary
Simulations Plus, Inc. (SLP) will participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference virtually from February 13-14, 2024. CEO Shawn O’Connor will present on February 13 at 11:20 a.m. Eastern Time. The live webcast will be available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
-
News

Simulations Plus Releases GastroPlus® Version 9.9

Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) announces the release of GastroPlus® 9.9, featuring expanded models for ocular, oral cavity, and dermal delivery routes, improved Biologics Module, and upgraded ADMET Predictor® version 11 models. The company collaborated with the FDA and other regulatory agencies, incorporating feedback from over 100 companies to enhance the software. The updates aim to improve the functionality and predictive capabilities of the platform, supporting program design and regulatory submissions for pharmaceutical industry and clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
News

Simulations Plus Embarks on Collaboration with Northeastern University and The TIM Company Through New FDA Grant

Rhea-AI Summary
Simulations Plus, Inc. (SLP) has been awarded a new funded grant from the U.S. Food and Drug Administration (FDA) to aid in the understanding of oral modified-release (MR) formulations and advance the development and approval of generic oral MR drug products through a joint proposal with Northeastern University and The TIM Company. The project will integrate experimental data and PBPK modeling to identify key formulation factors to accelerate modified-release product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
none

FAQ

What is the current stock price of Simulations Plus (SLP)?

The current stock price of Simulations Plus (SLP) is $30.04 as of November 21, 2024.

What is the market cap of Simulations Plus (SLP)?

The market cap of Simulations Plus (SLP) is approximately 570.9M.

What does Simulations Plus, Inc. do?

Simulations Plus develops modeling and simulation software and offers consulting services for drug discovery and development.

What are the main products of Simulations Plus?

Key products include GastroPlus™, ADMET Predictor™, KIWI™, DILIsym®, NAFLDsym®, and PKPlus™.

How does Simulations Plus support drug development?

The company provides data-driven modeling methodologies from early discovery through clinical trials and post-approval.

Who uses Simulations Plus technology?

Pharmaceutical companies and regulatory agencies worldwide utilize their technology.

What are the primary segments of Simulations Plus’ operations?

The primary segments are software and services.

Which subsidiaries are part of Simulations Plus?

Cognigen Corporation and DILIsym Services are subsidiaries of Simulations Plus.

How long has Simulations Plus been in operation?

The company has been in operation for over 20 years.

Where is Simulations Plus headquartered?

The company is headquartered in Lancaster, California.

Does Simulations Plus offer consulting services?

Yes, the company provides consulting and contract research services to the pharmaceutical industry.

How can I stay updated on Simulations Plus’ latest news?

You can visit the news section on their website to stay updated with the latest developments and achievements.

Stock SLP logo
Simulations Plus, Inc.

Nasdaq:SLP

SLP Rankings

#3004 Ranked by Market Cap
#1892 Ranked by Dividends

SLP Stock Data

570.91M
16.42M
18.14%
77.89%
4.88%
Health Information Services
Services-computer Integrated Systems Design
Link
United States of America
LANCASTER